|
Active Investor and Media Outreach to Build Company Awareness as a Leading Parthenogenetic Stem Cell Company International Stem Cell Corporation (OTCBB:ISCO), the first company to perfect a method of creating human stem cells from unfertilized eggs, has retained the Investor Relations Group (IRG), a highly recognized corporate communications firm based in New York City, to serve as its national investor and public relations firm. International Stem Cell is the first company to perfect a method of creating human stem cells from unfertilized eggs. These cells, called "parthenogenetic" stem cells, promise to avoid two critical problems inherent in cell transplantation today: immune rejection and the ethical issues associated with the use of fertilized human embryos. ISCO, through its wholly owned subsidiary, Lifeline Cell Technology, develops and manufactures cell culture products for research use and currently generates revenue and therapeutic production capacity for the Company. The Investor Relations Group's team will use proprietary competitive analysis strategies and extensive databases to target the broad scope of the investment community, including portfolio managers and analysts. IRG's program will include pre-qualified one-on-one introductions, e-mail campaigns to investment professionals that have opted-in for communication, and traditional outreach. Simultaneously, the thirteen-year-old firm's award-winning public relations department will initiate an outreach campaign to the media, namely editors, writers, and producers of local and national trade and consumer print publications, online portals, radio, and broadcast media outlets. Together the team's mandate will be to educate and communicate International Stem Cell's corporate strategy, key initiatives for growth, and ongoing company developments to both the investment community and general public. "We are at an inflection point in ISCO's history and we feel it is the right time for IRG to begin building awareness and communicating the story of our unique stem cell technology to the investment community, media-at-large, and general public," said Ken Aldrich, Chairman and CEO of International Stem Cell. "As we move forward with our vision for growth, we look forward to IRG relaying our corporate objectives to the appropriate target audiences." About The Investor Relations Group, Inc.: The Investor Relations Group, Inc. (IRG) offers a full-service corporate communications program designed to suit the many unique needs of public companies. The program utilizes a proprietary, targeted approach to reach institutional investors, analysts, and the media-at-large. For further information, please visit the company's website at www.investorrelationsgroup.com. About International Stem Cell Corporation: International Stem Cell Corporation (ISCO) is a California biotechnology company focused on developing therapeutic and research products. ISCO's technology, Parthenogenesis, results in the creation of pluripotent human stem cell lines from unfertilized human eggs. ISCO scientists also have created the first Parthenogenetic homozygous stem cell line (phSC-Hhom-4) that can be a source of therapeutic cells that will not be immune rejected after transplantation into millions of individuals of differing sexes, ages and racial groups. These advancements offer the potential to create the first true "Stem Cell Bank" and address ethical issues by eliminating the need to use or destroy fertilized embryos. ISCO also produces and markets specialized cells and growth media worldwide for therapeutic research through its subsidiary Lifeline Cell Technology. For more information, visit the ISCO website at: www.internationalstemcell.com. To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0. Forward-Looking Statements Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will,""believes,""plans,""anticipates,""expects,""estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements. The Investor Relations Group
212-825-3210
Investor Relations:
Adam Holdsworth
aholdsworth@investorrelationsgroup.com
or
Erica Ruderman
eruderman@investorrelationsgroup.com
or
Brett Foley
bfoley@investorrelationsgroup.com
or
Media Relations:
Laura Colontrelle
lcolontrelle@investorrelationsgroup.com |
